Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthonius de Boer

Showing results (191-200 of 282) with videos related to

Pageof 29
Sort By:
Drugs|August 11, 2004
Drug-gene interactions between genetic polymorphisms and antihypertensive therapyHedi Schelleman, Bruno H Ch Stricker, Anthonius De Boer, et al.
British Journal of Clinical Pharmacology|September 17, 2015
Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control studyJohannes T H Nielen, Frank de Vries, Pieter C Dagnelie, et al.
Clinical Therapeutics|August 13, 2020
Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority MarginsTurki A Althunian, Anthonius de Boer, Aukje K Mantel-Teeuwisse, et al.
Respiratory Medicine|October 28, 2018
Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013Olorunfemi A Oshagbemi, Spencer J Keene, Johanna H M Driessen, et al.
Platelets|December 15, 2010
Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patientsAnkie M Harmsze, Jochem W Van Werkum, Fulya Moral, et al.
Pharmacogenomics|July 27, 2017
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugsJoost W Geenen, Ekaterina V Baranova, Folkert W Asselbergs, et al.
British Journal of Clinical Pharmacology|April 25, 2021
Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based studyTalip E Eroglu, Lixia Jia, Marieke T Blom, et al.
International Journal of Clinical Pharmacy|July 11, 2015
Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitorsSeyed Hamidreza Mahmoudpour, Folkert W Asselbergs, Catherine E de Keyser, et al.
Pulmonary Pharmacology & Therapeutics|December 1, 2019
C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPDOlorunfemi A Oshagbemi, Frits M E Franssen, Emiel F M Wouters, et al.
Pharmacoepidemiology and Drug Safety|November 21, 2014
Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation studyMd Jamal Uddin, Rolf H H Groenwold, Tjeerd P van Staa, et al.
Pageof 29

Showing results (191-200 of 282) with videos related to

Sort By:
Pageof 29
Drugs|August 11, 2004
Drug-gene interactions between genetic polymorphisms and antihypertensive therapyHedi Schelleman, Bruno H Ch Stricker, Anthonius De Boer, et al.
British Journal of Clinical Pharmacology|September 17, 2015
Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control studyJohannes T H Nielen, Frank de Vries, Pieter C Dagnelie, et al.
Clinical Therapeutics|August 13, 2020
Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority MarginsTurki A Althunian, Anthonius de Boer, Aukje K Mantel-Teeuwisse, et al.
Respiratory Medicine|October 28, 2018
Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013Olorunfemi A Oshagbemi, Spencer J Keene, Johanna H M Driessen, et al.
Platelets|December 15, 2010
Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patientsAnkie M Harmsze, Jochem W Van Werkum, Fulya Moral, et al.
Pharmacogenomics|July 27, 2017
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugsJoost W Geenen, Ekaterina V Baranova, Folkert W Asselbergs, et al.
British Journal of Clinical Pharmacology|April 25, 2021
Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based studyTalip E Eroglu, Lixia Jia, Marieke T Blom, et al.
International Journal of Clinical Pharmacy|July 11, 2015
Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitorsSeyed Hamidreza Mahmoudpour, Folkert W Asselbergs, Catherine E de Keyser, et al.
Pulmonary Pharmacology & Therapeutics|December 1, 2019
C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPDOlorunfemi A Oshagbemi, Frits M E Franssen, Emiel F M Wouters, et al.
Pharmacoepidemiology and Drug Safety|November 21, 2014
Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation studyMd Jamal Uddin, Rolf H H Groenwold, Tjeerd P van Staa, et al.
Pageof 29